Thyrocare Technologies Limited has informed the Exchange about Investor Presentation
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Thyrocare reported Q1 FY26 consolidated revenue of ₹193 Cr, up 23% YoY, driven by 25% growth in pathology and 6% in radiology. Normalized EBITDA grew 42% YoY with margins expanding 354 basis points to 33%, while reported EBITDA rose 37% YoY. Profit after tax jumped 62% YoY to ₹38.06 Cr. The company processed 46.9 million tests (+15% YoY) for 4.6 million patients (+12% YoY), with active franchisees rising 17% to 9,551. Key operational updates included a new Regional Processing Lab in Bhagalpur, Bihar, and two new partner labs in Kashmir and Roorkee. Management highlighted continued focus on deepening franchise and partnership networks, PPP business, and Tanzania expansion as future growth pillars.
Strong beat on profitability with significant margin expansion and 62% PAT growth signals improving operating leverage and quality of growth. Positive for shareholder sentiment, though the stock has been a Pharma Easy/API Holdings group company with parent-level ESOP charges still flowing through reported numbers.